Results 201 to 208 of about 25,089 (208)

No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3

European Journal of Clinical Pharmacology, 2003
Tsuyoshi Fukuda, Yoshihiko Funae
exaly  

Clinical significance of CYP2C9‐status guided valproic acid therapy in children

Epilepsia, 2015
Katalin Monostory, Miklós Garami
exaly  

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9 * 3 allele

European Journal of Clinical Pharmacology, 2000
Ichiro Ieiri, K Otsubo
exaly  

Frequency of CYP2C9 alleles in Koreans and their effects on losartan pharmacokinetics

Acta Pharmacologica Sinica, 2011
Jung-Woo Bae, Choon-Gon Jang, Seok-Yong Lee   +2 more
exaly  

In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population

Acta Pharmacologica Sinica, 2013
Hu Guoxin, Shuanghu Wang, Da-Peng Dai
exaly  

Effects of CYP2C9 * 1/ * 13 on the pharmacokinetics and pharmacodynamics of meloxicam

British Journal of Clinical Pharmacology, 2011
Jung-Woo Bae, Choon-Gon Jang, Seok-Yong Lee   +2 more
exaly  

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Lancet, The, 1999
Ann Daly, Guruprasad Aithal, Christopher P Day   +2 more
exaly  

Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics

Journal of Clinical Pharmacy and Therapeutics, 2012
exaly